Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Celldex Therapeutics, Inc. (CLDX) had Free Cash Flow per Share of $-3.22 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$1.54M |
|
$-258.76M |
|
-- |
|
$1.54M |
|
$288.91M |
|
$-287.37M |
|
$28.61M |
|
$-258.76M |
|
$-258.76M |
|
$-258.76M |
|
$-258.76M |
|
$-258.76M |
|
$-258.76M |
|
$-287.37M |
|
$-289.84M |
|
66.42M |
|
66.42M |
|
$-3.90 |
|
$-3.90 |
|
| Balance Sheet Financials | |
$534.66M |
|
$5.33M |
|
$48.32M |
|
$582.98M |
|
$50.99M |
|
-- |
|
$4.83M |
|
$55.82M |
|
$527.16M |
|
$499.98M |
|
$527.16M |
|
66.55M |
|
| Cash Flow Statement Financials | |
$-210.94M |
|
$209.07M |
|
$2.39M |
|
$28.36M |
|
$28.87M |
|
$0.52M |
|
$36.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.49 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
100.00% |
|
-18599.81% |
|
-18599.81% |
|
-18760.00% |
|
-16748.03% |
|
-16748.03% |
|
$-213.66M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.77 |
|
476.04 |
|
-49.08% |
|
-51.75% |
|
-44.38% |
|
-49.08% |
|
$7.92 |
|
|
Free Cash Flow per Share |
$-3.22 |
$-3.18 |
|